PADI2 and prostate carcinoma: In preclinical models of breast cancer,28, 29, 30, 31, 32 prostate cancer,21, 33 gastric cancer,20 and glioblastoma,34 PADI2 inhibition or depletion decreased growth, migration, and extracellular vesicle release, and was synergistic with docetaxel and bortezomib in inducing apoptosis in tamoxifen‐resistant breast cancer 22 and bone marrow mesenchymal stem cells,35 respectively.